Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center. Issue 6 (December 2019)

• Record Type: Journal Article
• Authors: Stenehjem, David D.; Au, Trang H.; Ngorsuraches, Surachat; Ma, Junjie; Bauer, Hillevi; Wanishayakorn, Tanatape; Nelson, Ryan S.; Pfeiffer, Constance M.; Schwartz, Joshua; Korytowsky, Beata; Oderda, Gary; Brixner, Diana I.
• Is Part Of: Melanoma research. Volume 29:Issue 6(2019)
• Publication Date: 2019-12
• Subjects: combination immunotherapy -- discrete choice experiment -- patient and provider preference -- willingness-to-pay; Melanoma -- Periodicals; Melanoma -- Periodicals; Melanomen; 616.99477
• DOI: 10.1097/CMR.0000000000000572
• Languages: English
• ISSNs: 0960-8931

Abstract

Abstract : New melanoma therapies have shifted the expectations of patients and providers. Evaluating the impact of treatment characteristics may enhance shared decision making. A survey, including a discrete choice experiment, was utilized to evaluate perceived trade-offs of different melanoma treatments and to estimate out-of-pocket (OOP) willingness-to-pay (WTP) thresholds (January 2016 to March 2016). Participants included patients with melanoma at Huntsman Cancer Institute and their cancer care providers. Stakeholder focus groups were conducted to identify treatment attributes. Descriptive and comparative statistics and multinomial logit model were used to evaluate responses. Response rates were 41.9% ( N = 220) for patients and 37.7% ( N = 20) for providers. Immunotherapy and targeted therapy attributes considered important by participants were overall survival, immunotherapy-related side effects, and skin toxicities. Patients and providers had significantly different views of quality-of-life expectations, anxiety toward melanoma, trust to make treatment decisions, sharing concerns about treatment, time to discuss treatment, understanding OOP costs, and willingness to undergo/recommend treatment (half of the patients would undergo treatment if it was effective for > 24 months). Among patients, the average monthly OOP WTP for combination immunotherapy with nivolumab + ipilimumab was $ 2357 and for BRAF/MEK inhibitor was $1648. Among providers, these estimates were $ 2484 and $1350, respectively. Discordance existed between patients' and providers' perceptions about quality of life expectations, degree of anxiety, sharing of opinions, and progression-free survival. Our study suggests that patients and providers exhibit a higher OOP WTP for combination immunotherapy treatment compared with BRAF/MEK inhibitors, influenced predominately by overall survival expectations. Abstract : Supplemental Digital Content is available in the text.